PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi, will present at the 23rd Annual Needham Virtual Healthcare Conference taking place April 8-11, 2024. During her presentation, Ms. Ricciardi will review recent corporate accomplishments and anticipated clinical milestones. Details of C ...

临床试验和FDA审批 - 公司专注于治疗AD，目前市场上只有两种治疗选项获得FDA批准[212] - 公司需要成功进行关键临床试验以获得FDA批准，但可能面临挑战[213] - 虽然获得FDA的突破性疗法认定可能有利于产品发展，但并不一定加快审批过程[214] - 公司的CT1812获得FDA的快速通道认定，但也不一定加快审批过程[215] - FDA和其他政府机构的资金短缺或全球卫生问题可能影响审批过程[217] - 公司在美国以外进行的临床试验数据可能不被FDA和其他国外监管机构接受[218] 商业风险和挑战 - 如果公司无法成功发现、开发和商业化其他产品候选药物，商业机会可能受限[221] - 公司的商业成功高度依赖于CT1812的成功发展和商业化，但存在风险[226] - 公司需要扩大组织规模，可能会遇到管理增长的困难[227] - 公司未来的财务表现和产品开发能力将部分取决于有效管理未来的增长[229] - 吸引和留住高级管理人员和关键科学人员对公司的成功至关重要[230] 销售和监管挑战 - 公司目前没有销售组织，需要建立销售能力，否则可能无法有效在美国和国外市场推广和销售产品候选人[310] - 产品候选人获得批准后，将面临持续的监管要求，包括制造、标签、包装、存储、广告、推广等方面的要求[311] - 如果监管机构发现产品存在问题，可能会对产品或公司施加限制，包括要求撤回产品[313] 法律和合规风险 - 公司可能会因违反相关法律法规而面临重大的民事、刑事和行政制裁[321] - 税收法律和法规的变化可能对公司的业务、财务状况和运营结果产生重大不利影响[323] - 公司受美国和某些外国出口和进口控制、制裁、禁运、反腐败法律和反洗钱法律法规的约束，遵守这些法律标准可能损害公司在国内和国际市场上的竞争能力[324] 金融和上市风险 - 金融服务行业的不利发展可能对公司的业务、财务状况或经营业绩产生不利影响[344] - 投资者对美国或国际金融体系的担忧可能导致商业融资条件恶化，包括更高的利率或成本以及更严格的财务和经营契约[347] - 公司可能面临证券诉讼，这将是昂贵的并可能分散管理层的注意力[348] - 作为一家上市公司，公司将继续承担重大成本，管理层将投入大量时间进行新的合规倡议[350] - 公司可能会因为成为一家上市公司而承担增加的成本和对管理层的要求[352]

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Conference Call March 26, 2024 8:00 AM ET Company Participants Lisa Ricciardi - President & CEO John Doyle - CFO Tony Caggiano - CMO & Head of R&D Mike Moyer - IR, LifeSci Advisors Conference Call Participants Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Mayank Mamtani - B. Riley Securities Operator Hello, everyone, and welcome to Cognition Therapeutics Fourth Quarter 2023 Earnings Call. Please note that this call is being recorded. I ...

Exhibit 99.1 Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update - Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 - - On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 - - Webcast Conference Call Scheduled Today at 8:00 a.m. ET - Purchase, NY – March 26, 2024 – Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company de ...

PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open. Following the release, management will host a conference call at 8:00 a.m. ET ...

PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open. Following the release, management will host a conference call at 8:00 a.m. ET ...

PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. ("Cognition," the "Company" or "We") (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock. Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its com ...

公开发行 - Cognition Therapeutics, Inc.宣布启动普通股公开发行[1] - Titan Partners Group是本次发行的唯一簿记管理人[2] - 本次发行是根据之前在2013年12月23日提交给美国证券交易委员会的有效“货架”注册声明（文件编号333-268992）进行的[3] 公司介绍 - Cognition Therapeutics, Inc.是一家临床阶段的生物制药公司，致力于发现和开发针对中枢神经系统和视网膜的老年退行性疾病的创新小分子治疗药物[5]

PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUE ...

PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company's president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024. During her presentation, Ms. Ricciardi will highlight Cognition's pipeline progress, including upcoming clinical milestones and recent corporate achievem ...